Literature DB >> 34169641

Identifying treatment effects using trimmed means when data are missing not at random.

Alex Ocampo1, Heinz Schmidli2, Peter Quarg2, Francesca Callegari2, Marcello Pagano1.   

Abstract

Patients often discontinue from a clinical trial because their health condition is not improving or they cannot tolerate the assigned treatment. Consequently, the observed clinical outcomes in the trial are likely better on average than if every patient had completed the trial. If these differences between trial completers and non-completers cannot be explained by the observed data, then the study outcomes are missing not at random (MNAR). One way to overcome this problem-the trimmed means approach for missing data due to study discontinuation-sets missing values as the worst observed outcome and then trims away a fraction of the distribution from each treatment arm before calculating differences in treatment efficacy (Permutt T, Li F. Trimmed means for symptom trials with dropouts. Pharm Stat. 2017;16(1):20-28). In this paper, we derive sufficient and necessary conditions for when this approach can identify the average population treatment effect. Simulation studies show the trimmed means approach's ability to effectively estimate treatment efficacy when data are MNAR and missingness due to study discontinuation is strongly associated with an unfavorable outcome, but trimmed means fail when data are missing at random. If the reasons for study discontinuation in a clinical trial are known, analysts can improve estimates with a combination of multiple imputation and the trimmed means approach when the assumptions of each hold. We compare the methodology to existing approaches using data from a clinical trial for chronic pain. An R package trim implements the method. When the assumptions are justifiable, using trimmed means can help identify treatment effects notwithstanding MNAR data.
© 2021 John Wiley & Sons Ltd.

Entities:  

Keywords:  clinical trials; estimands; missing data; trimmed means

Mesh:

Year:  2021        PMID: 34169641      PMCID: PMC9051568          DOI: 10.1002/pst.2147

Source DB:  PubMed          Journal:  Pharm Stat        ISSN: 1539-1604            Impact factor:   1.234


  8 in total

1.  Principal stratification in causal inference.

Authors:  Constantine E Frangakis; Donald B Rubin
Journal:  Biometrics       Date:  2002-03       Impact factor: 2.571

2.  Missing data in clinical trials: control-based mean imputation and sensitivity analysis.

Authors:  Devan V Mehrotra; Fang Liu; Thomas Permutt
Journal:  Pharm Stat       Date:  2017-06-20       Impact factor: 1.894

3.  An evaluation of the trimmed mean approach in clinical trials with dropout.

Authors:  Ming-Dauh Wang; Jiajun Liu; Geert Molenberghs; Craig Mallinckrodt
Journal:  Pharm Stat       Date:  2018-04-06       Impact factor: 1.894

4.  Methods for dealing with time-dependent confounding.

Authors:  R M Daniel; S N Cousens; B L De Stavola; M G Kenward; J A C Sterne
Journal:  Stat Med       Date:  2012-12-03       Impact factor: 2.373

5.  Trimmed means for symptom trials with dropouts.

Authors:  Thomas Permutt; Feng Li
Journal:  Pharm Stat       Date:  2016-08-15       Impact factor: 1.894

6.  Estimands in clinical trials - broadening the perspective.

Authors:  Mouna Akacha; Frank Bretz; Stephen Ruberg
Journal:  Stat Med       Date:  2016-07-19       Impact factor: 2.373

Review 7.  Neurophysiological evaluation of pain.

Authors:  B Bromm; J Lorenz
Journal:  Electroencephalogr Clin Neurophysiol       Date:  1998-10

8.  Analysis of longitudinal trials with protocol deviation: a framework for relevant, accessible assumptions, and inference via multiple imputation.

Authors:  James R Carpenter; James H Roger; Michael G Kenward
Journal:  J Biopharm Stat       Date:  2013       Impact factor: 1.051

  8 in total
  1 in total

1.  Sensitivity to missing not at random dropout in clinical trials: Use and interpretation of the trimmed means estimator.

Authors:  Audinga-Dea Hazewinkel; Jack Bowden; Kaitlin H Wade; Tom Palmer; Nicola J Wiles; Kate Tilling
Journal:  Stat Med       Date:  2022-01-31       Impact factor: 2.497

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.